Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | CA1 | P00915 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 4/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21153279 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9PLG | |
| SCHEMBL21152627 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9PLG | |
| SCHEMBL19983271 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9PLG | |
| SCHEMBL19983026 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9PLG | |
| SCHEMBL30716860 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9PLG | |
| SCHEMBL23023452 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9PLG | |
| SCHEMBL22292196 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9PLG | |
| SCHEMBL21152460 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9PLG | |
| SCHEMBL22292204 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9PLG | |
| SCHEMBL21152626 | 0.95 | CA12 (0.55) | CA12CA1CA2CA9PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4480541-A2 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Lighthouse Pharmaceuticals, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12110263-B2 | Ketone inhibitors of lysine gingipain | LIGHTHOUSE PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-3512846-B1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | LIGHTHOUSE PHARMACEUTICALS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
| US-12110263-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
| US-20250270162-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | CA12 1194/4885CA1 262/4885CA2 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.